| 12377152 |
Compounds for degrading alpha-synuclein aggregates and uses thereof |
Ming-Kuei JANG, Yih-Shyan Lin |
2025-08-05 |
|
| 12116364 |
Heteroaryl compounds and uses thereof |
Ming-Kuei JANG |
2024-10-15 |
|
| 11655216 |
Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use |
Michael T. Rudd, Zhaoyang Meng, Jenny Wai, David Jonathan Bennett, Edward J. Brnardic +6 more |
2023-05-23 |
$435,980,000 |
| 11642413 |
Compounds for degrading Tau protein aggregates and uses thereof |
Ming-Kuei JANG, Yih-Shyan Lin |
2023-05-09 |
|
| 11291732 |
Compounds for degrading α-synuclein aggregates and uses thereof |
Ming-Kuei JANG, Yih-Shyan Lin |
2022-04-05 |
|
| 11046714 |
2,2-difluorodioxolo A2A receptor antagonists |
Ali Amjad, Gioconda V. Gallo, Timothy J. Henderson, Rongze Kuang, Yeon-Hee Lim +6 more |
2021-06-29 |
$135,073,000 |
| 10961215 |
N-aryl and N-heteroaryl piperidine derivatives as liver X receptor beta agonists, compositions, and their use |
Michael T. Rudd, Zhaoyang Meng, Jenny Wai, David Jonathan Bennett, Edward J. Brnardic +5 more |
2021-03-30 |
$232,732,000 |
| 10941152 |
Pyrazole compounds as modulators of FSHR and uses thereof |
Henry Yu, Changhe Qi, Selvaraj Nataraja, Stephen Palmer |
2021-03-09 |
|
| 10894775 |
Piperidine derivatives as liver X receptor beta agonists, compositions, and their use |
Michael T. Rudd, Zhaoyang Meng, Jenny Wai, David Jonathan Bennett, Edward J. Brnardic +7 more |
2021-01-19 |
$373,637,000 |
| 10822338 |
Substituted aminoquinazoline compounds as A2A antagonist |
Amjad Ali, Xianhai Huang, Yeon-Hee Lim, Rongze Kuang, Heping Wu +6 more |
2020-11-03 |
$132,407,000 |
| 10208055 |
Pyrazole compounds as modulators of FSHR and uses thereof |
Henry Yu, Changhe Qi, Selvaraj Nataraja, Stephen Palmer |
2019-02-19 |
|
| 10011615 |
Heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with A2A anatagonist properties |
Amjad Ali, Michael Man-Chu Lo, Yeon-Hee Lim, Andrew Stamford, Rongze Kuang +14 more |
2018-07-03 |
$73,356,000 |
| 9688654 |
Compounds inhibiting leucine-rich repeat kinase enzyme activity |
Michael Miller, Kallol Basu, Duane DeMong, Jack D. Scott, Hong Liu +3 more |
2017-06-27 |
$105,730,000 |
| 9676780 |
Piperazine-substituted [1,2,4]triazolo[1,5-C]quinazolin-5-amine compounds with A2A antagonist properties |
Amjad Ali, Michael Man-Chu Lo, Yeon-Hee Lim, Andrew Stamford, Rongze Kuang +19 more |
2017-06-13 |
$92,938,000 |
| 9493440 |
Compounds inhibiting leucine-rich repeat kinase enzyme activity |
Michael Miller, Kallol Basu, Duane DeMong, Jack D. Scott, Wei Li +2 more |
2016-11-15 |
$49,512,000 |
| 9416126 |
Compounds inhibiting leucine-rich repeat kinase enzyme activity |
Michael Miller, Kallol Basu, Duane DeMong, Jack D. Scott, Wei Li +3 more |
2016-08-16 |
$77,022,000 |
| 9096559 |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
Paul E. Harrington, Richard W. Heidebrecht, Solomon D. Kattar, Thomas Miller, Karin M. Otte +4 more |
2015-08-04 |
$86,770,000 |
| 8759579 |
Cyclobutyl sulfones as notch sparing gamma secretase inhibitors |
Richard W. Heidebrecht, Chaomin Li, Benito Munoz, Andrew Rosenau, Laura M. Surdi |
2014-06-24 |
$70,429,000 |
| 8686020 |
Spirocyclic compounds |
Christopher Hamblett, Joey L. Methot, Thomas Miller, David L. Sloman, Matthew G. Stanton +1 more |
2014-04-01 |
$62,211,000 |
| 8389553 |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
Paul E. Harrington, Solomon D. Kattar, Thomas Miller, Matthew G. Stanton, David J. Witter |
2013-03-05 |
$77,218,000 |
| 8367706 |
Inhibitors of janus kinases |
Michael D. Altman, Matthew Christopher, Jonathan B. Grimm, Andrew M. Haidle, Kaleen Konrad +12 more |
2013-02-05 |
$75,079,000 |
| 8349825 |
Spirocyclic compounds |
Dawn M. Mampreian, Joey L. Methot, Thomas Miller, Anna A. Zabierek |
2013-01-08 |
$59,014,000 |
| 8158825 |
Modified malonate derivatives |
Jonathan B. Grimm, Paul E. Harrington, Richard W. Heidebrecht, Thomas Miller, Karin M. Otte +6 more |
2012-04-17 |
$210,725,000 |
| 8119652 |
Aryl-fused spirocyclic compounds |
Christopher Hamblett, Solomon D. Kattar, Dawn M. Mampreian, Joey L. Methot, Thomas Miller |
2012-02-21 |
$50,558,000 |
| 8026260 |
Histone deacetylase inhibitors with aryl-pyrazolyl-motifs |
Joshua Close, Richard W. Heidebrecht, Solomon D. Kattar, Thomas Miller, David L. Sloman +2 more |
2011-09-27 |
$97,020,000 |
